Thera-SAbDab

GREMUBAMAB

>   Structural Summary
TherapeuticGremubamab
Target 1PcrV type III secretion system
Heavy Chain 1EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGKGLEWVSAITMSGITAYYTDDVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEEFLPGTHYYYGMDVWGQGTTVTVSS
Light Chain 1AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYSASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIK
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 Structure6cyf [Fvs: DC, FE, ML, UT]
Target 2Polysaccharide synthesis locus (Pseudomonas)
Heavy Chain 2QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWGQGTMVTVSS
Light Chain 2DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGCGTKVEIK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Gremubamab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 98.70%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 100E 100F 100G 101 102 103 104 105 106 107 108 109 110 111 112 113
gremubamab_Fv1 E V Q L L E S G G G L V Q P G G S L R L S C A A S G F T F S S Y A M N W V R Q A P G K G L E W V S A I T M S G I T A Y Y T D D V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K E E F L P G T H Y Y Y G M D V W G Q G T T V T V S S
6cyf E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S S Y A M D W V R Q A P G K G L E W V S A I T M S G I T A Y Y T D D V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A V Y Y C A K E E F L P G T H Y F Y G M D V W G Q G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
gremubamab_Fv1 A I Q M T Q S P S S L S A S V G D R V T I T C R A S Q G I R N D L G W Y Q Q K P G K A P K L L I Y S A S T L Q S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C L Q D Y N Y P W T F G Q G T K V E I K
6cyf A I Q M T Q S P S S L S A S V G D R V T I T C R A S Q G I R N D L G W Y Q Q K P G K A P K L L I Y S A S T L Q S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C L Q D Y N Y P W T F G Q G T K V E I K
>   Metadata
FormatBispecific mAb
IsotypeG1;G1
Highest Clinical Trial (Aug '23)Phase-II
Estimated Status (Aug '23)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year Recommended2020
Companies InvolvedMedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedNosocomial pneumonia
Notes(May '22) Added missing Y102 in Fv1 LC.

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy